A clinical study of esucos in a mentally retarded clientele.
D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D001925:Brain Damage, Chronic / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D004775:Enuresis / Q000188:drug therapy; D001068:Feeding and Eating Disorders / Q000188:drug therapy; D005260:Female; D006613:Higher Nervous Activity / Q000187:drug effects; D006801:Humans; D006919:Hydroxyzine / Q000494:pharmacology / Q000627:therapeutic use*; D008607:Intellectual Disability / Q000150:complications; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D010919:Placebos; D011395:Promazine / Q000494:pharmacology / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013981:Tic Disorders / Q000188:drug therapy
D010919:Placebos; D006919:Hydroxyzine; D011395:Promazine